Please login to the form below

Not currently logged in
Email:
Password:

OncoMed’s CMO steps down

Dr Jakob Dupont to leave the clinical-stage company

OncoMed Pharmaceuticals' Dr Jakob Dupont has resigned as senior vice president and chief medical officer, and is due to step down from 1 January 2017.

Dr Dupont first joined the California-based oncology specialist in 2011, having moved from Roche where he was global medical director of Avastin.

Prior to this, Dr Dupont was director of early and late stage development at Genentech, and served as a researcher in tumour immunology at the Memorial Sloan Kettering Cancer Center.

Paul Hastings, OncoMed's chairman and chief executive officer, said: “It is with great sadness that we announce Jakob's resignation.

“During his five-year tenure, Jakob has built an impressive clinical development team that is advancing seven novel anti-cancer investigational drugs in the clinic, including earlier this year, completion of enrollment in our YOSEMITE and PINNACLE randomized phase II trials.

“Although we regret Jakob's departure, we respect his decision and wish him all the best, and thank him for his many significant contributions to the company."

3rd January 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics